Welcome to our dedicated page for XOMA Royalty news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty stock.
XOMA Royalty Corporation operates as a biotechnology royalty aggregator that acquires rights to potential milestone and royalty payments tied to therapeutic candidates licensed to pharmaceutical and biotechnology companies. Its updates commonly address portfolio additions, royalty-sharing transactions, commercial and development-stage assets, clinical and regulatory disclosures from underlying programs, and cash receipts from royalties and milestones.
Company news also covers financial results, preferred stock dividends on its Series A and Series B cumulative preferred securities, completed acquisitions that expand the royalty portfolio, and executive or governance changes. Named portfolio assets include VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, DARE to PLAY, DSUVIA, and development-stage assets such as mezagitamab.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.